Tissue-Agnostic Drug Development in Cancer (2nd Edition)
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Drug Development".
Deadline for manuscript submissions: 30 November 2025 | Viewed by 1054
Special Issue Editors
Interests: developing new treatments for cancer
Special Issues, Collections and Topics in MDPI journals
2. Kirk Kerkorian School of Medicine, University of Nevada, Las Vegas (UNLV), 4505 S. Maryland Pkwy, Las Vegas, NV 89154, USA
Interests: phase 1 (investigational cancer therapeutics); thyroid; head and neck cancers
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
This Special Issue is the second edition of “Tissue-Agnostic Drug Development in Cancer”.
The utilization of molecular genetics and biomarker-driven strategies for treatment selection has led to the concept of tissue-agnostic drug development. Histology-driven drug development has been the norm for decades, but recent advancements have focused efforts on tissue-agnostic drug development depending on the biological context. Regulatory approvals of larotrectinib and entrectinib for the treatment of neurotrophic tyrosine kinase (NTRK)-fusion-positive solid tumors, dabrafenib plus trametinib for unresectable or metastatic solid tumors with BRAFV600E mutations, and selpercatinib in the treatment of locally advanced or metastatic rearranged during transfection (RET) fusion-positive solid tumors are examples of targeted agents approved broadly across histologies. The tissue-agnostic regulatory approval of immunotherapies (for example, pembrolizumab for the treatment of unresectable or metastatic, microsatellite instability-high (MSI-H), or deficient mismatch repair (dMMR) solid tumors, and of tumor mutational burden-high (TMB-H) tumors; and dostarlimab-gxly for the treatment of mismatch-repair-deficient recurrent or advanced solid tumors) has further heightened interest in tissue-agnostic drug development.
This Special Issue will cover recent tissue-agnostic drug approvals, the emergence of drug resistance and strategies to overcome it, and lessons learned by conducting multihistology trials in relatively rare subsets of cancers. Recent successes have created an exciting new avenue to approach drug development in cancer and improve outcomes for patients with a variety of tumors.
Dr. Shivaani Kummar
Dr. Kyaw Thein
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- tissue-agnostic drug development
- pembrolizumab
- microsatellite instability-high (MSI-H)
- tumor mutational burden-high (TMB-H)
- dostarlimab-gxly
- larotrectinib
- entrectinib
- neurotrophic tyrosine kinase (NTRK)-fusion-positive solid tumors
- dabrafenib and trametinib
- selpercatinib
- rearranged during transfection (RET) gene fusion
- precision medicine
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.
Related Special Issue
- Tissue Agnostic Drug Development in Cancer in Cancers (5 articles)
